CONMED's Pivot: Portfolio Focus, Tariff Windfalls, and an AirSeal Tug-of-War
The med-tech orphan finally catches a bid as management reshapes the portfolio and the balance sheet, even as its flagship growth engine shows fatigue.
CNMD · Earnings Call · 2026-07-29
A Quarter of Mixed Signals
CONMED (CNMD) reported a second quarter that beat expectations on both the top and bottom line, but the story is far from straightforward. Net sales came in at $343.5 million, with organic growth of 6% — modestly exceeding the high end of guidance. CEO Pat Beyer highlighted the strength:Yet the headline EPS was flattered by a $0.21 tariff-refund benefit — an item that is both non-recurring and a direct result of the chaotic trade-policy environment. New CFO John Gallagher was careful to separate the noise from the signal: “The increase was driven primarily by an $8.5 million benefit from tariff refunds recognized during the quarter, representing approximately 250 basis points year-over-year.” — John Gallagher, Chief Financial Officer · 2026-07-29 Exclude that benefit, and gross margin still expanded 50 basis points, but operating margin was essentially flat — a more sober picture. The stock has responded viscerally, up 39% over the last 90 days (the full Price to Revenue ratio sits at 0.8x after a 79% drawdown from its 2021 peak). The market is clearly betting that the strategic refocus is starting to pay off.we delivered adjusted diluted earnings per share of $1.38, an increase of 20% year-over-year. These results were significantly better than the high end of our expectations.
Strategic Refocus and a Clean House
Management made several moves that go beyond the quarter: completing the exit from gastroenterology (GI) products, refinancing debt, and appointing a new CFO. The portfolio optimization is now final, and Beyer was explicit about the go-forward identity: “We've sharpened our focus on our strongest growth opportunities, minimally invasive robotic and laparoscopic surgery, smoke evacuation and the surgical treatment of orthopedic soft tissue repair.” — Patrick Beyer, Chief Executive Officer · 2026-07-29 This is a clear pivot. The GI product exit removes a drag and allows the company to concentrate on higher-margin, faster-growing categories. The refinancing — drawing on a new $450 million term loan to repurchase $645.2 million of convertible notes — simplifies the capital structure and pushes maturities out to 2030. The company also brought in a new CFO, John Gallagher, a veteran of BD and public healthcare firms, signaling a fresh financial discipline. From the prior quarter's call, then-CFO Todd Garner had already framed the debt strategy: “we determined that it was not in the best interest of CONMED shareholders to do new convertible notes at this time.” — Todd Garner, Chief Financial Officer (CFO) or Acting CFO · 2026-04-30 That decision now looks prescient given the stock's recovery. The tariff refund is a shared theme across the med-tech space this earnings season (GE HealthCare, for instance, also recognized IEEPA refunds), but the way CONMED has turned it into a one-off EPS boost while maintaining the full-year guidance is notable.AirSeal: The Engine That Sputters
The most controversial spot is AirSeal, the advanced insufflation platform that has been the company's flagship growth story. It remains the top contributor to General Surgery growth, but the growth rate was lower than expected. Beyer acknowledged this directly: “the level of AirSeal growth in the quarter was lower than we had expected. Looking ahead, we continue to expect improving AirSeal growth trends in the second half of 2026, albeit at a lower rate than our prior guidance assumed.” — Patrick Beyer, Chief Executive Officer · 2026-07-29 Still, the long-term thesis remains intact, buttressed by a new clinical indication. The AirSeal Robotic solution is now cleared for use with Intuitive's 8-millimeter Hex cannulas, expanding compatibility across the entire multiport da Vinci portfolio. This is a Hex cannula milestone that management says it had already embedded in guidance, but it should help drive attachment rates high single-digit growth for the year. Investors had previously been told that AirSeal's attach rate to DV5 was in the 10–20% range, and the company continues to exude confidence in the broader robotic and laparoscopic opportunity. Yet the deceleration is real, and the second-half guidance implies a more modest acceleration than originally planned.Ortho and Smoke: The Quiet Accelerators
Orthopedic Surgery sales grew 6.8%, led by international strength (up 10.8%), while the U.S. was flat. The Rotator cuff procedure remains the biggest opportunity, with BioBrace RC (the streamlined version) now a year into its launch. Beyer cited clinical evidence of a 94% healing rate in high-risk patients — a powerful message for surgeons who worry about retears. On the smoke evacuation front, Buffalo Filter continues to ride a legislative tailwind. Michigan and Maryland just passed smoke-free operating room laws, bringing the total to 22 states covering ~57% of the U.S. population. More than 10 additional states have bills pending. This is a long-term growth driver that is still early in its adoption curve.The company raised its full-year adjusted EPS guidance to $4.48–$4.60 from $4.30–$4.45, but this was largely a function of the tariff refund and a lower GI headwind, offset by higher interest expense and a higher tax rate. The organic revenue guidance for the year was trimmed at the high end to 5%–6%, reflecting a more measured AirSeal trajectory. ## The Bottom Line CONMED is in the midst of a deliberate transformation. The portfolio is leaner, the balance sheet is cleaner (interest coverage has improved from 3.6x at the last filing to 4.9x on a trailing basis), and the leadership team is largely new. But the market's enthusiasm is already priced into a 39% rally. The key question is whether AirSeal can re-accelerate and whether BioBrace can scale. The company's ability to deliver on the 2026 guidance of ~5–6% organic growth will be the proving ground. With a Operating Margin at 8.0% (down from 15.4% in 2024Q3), there is ample room for margin recovery — but only if the growth engines cooperate. The quarter was a step in the right direction, but the true test lies ahead.We also see evidence of continued activity on this front, including more than 10 additional states with bills on this subject entered and pending passage.